Systemic vs Local Consolidative Therapy for Metastatic Cancer

Palo Alto (17 mi)

Overseen byChad Tang

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This phase II trial studies how well systemic therapy with or without local consolidative therapy work in treating patients with solid tumor that has spread to 1 site of other places in the body. Treatment with up-front local consolidative therapy may be better in helping to control the disease.

Eligibility Criteria

This trial is for patients with a solid tumor that has spread to no more than 5 other sites (oligometastatic). They should have had fewer than 4 prior systemic treatments, be able to undergo local therapy, and have an ECOG performance status of 0-2. Key blood and liver function levels must meet specific criteria. Those with certain rheumatologic diseases, diffuse metastases, psychiatric or substance abuse issues, pregnant women, or those at risk of pregnancy are excluded.

Inclusion Criteria

I am able to get out of my bed or chair and move around.

I have 5 or fewer cancer spread sites.

I have had 4 or fewer treatments for my cancer that has spread.

My cancer diagnosis has been confirmed by lab tests.

Exclusion Criteria

My cancer has spread widely and cannot be fully treated, according to my doctor.

I've completed all possible curative treatments for my metastatic disease as advised by my oncologist, but still have the disease.

Treatment Details

The study is examining the effectiveness of standard systemic therapy alone versus combined with local consolidative therapy in controlling cancer that has spread but remains limited in number. The goal is to determine if adding targeted treatment directly to each cancer site can better manage the disease.

2Treatment groups

Experimental Treatment

Group I: Arm II (routine therapy)Experimental Treatment1 Intervention

Patients receive routine drug therapy. Patients may later receive LCT at the discretion of doctor.

Group II: Arm I (LCT, routine therapy)Experimental Treatment2 Interventions

Patients receive up-front standard of care LCT including but not limited to surgical resection, cryotherapy, and radiofrequency ablation. Patients then receive routine drug therapy.